Did our AI summary help? Imagine standing on stage in front of thousands of people. The lights are hot, all eyes are on you and suddenly someone from the audience decides to take a public swing at you ...

The path from contender to champion is rarely the same for NFL teams. Yet, the blueprint offered by the Super Bowl champion Seattle Seahawks provides valuable insight for the Detroit Lions as they ...

Even in advance of the results of an ongoing phase 3 trial in patients with cutaneous lupus erythematosus (CLE), anifrolumab — a monoclonal antibody targeting interferon — might not be best reserved ...

Like most tech leaders, I’ve spent the last year swimming in the hype: AI will replace developers. Anyone can build an app with AI. Shipping products should take weeks, not months. The pressure to use ...

Like many of you, I grew up watching It’s a Wonderful Life on television every holiday season. Frank Capra’s beloved film was a comforting part of our holiday tradition, often playing in the ...

If my three-decade journey in the corporate world has taught me anything, it’s that in business, as in life, the only certainty is uncertainty. In the past 20 years, periods of upheaval, from ...

Our annual conference, which this year coincided with the magazine’s 25th birthday, was a roaring success. For those who weren’t there, here is an overview of what you missed. Andrew opened ...

Following a night of Democratic electoral victories in New York City, Virginia, New Jersey, California and elsewhere, one-time GOP presidential candidate and former DOGE chief Vivek Ramaswamy admitted ...

Add Yahoo as a preferred source to see more of our stories on Google. Local musician, educator, and leader celebrates the release of his inspiring new book From One Stage to Another, a heartfelt ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...

Regeneron (NASDAQ:REGN) announced on Wednesday that its investigational treatment garetosmab reached the main goal in a Phase 3 trial for adults with fibrodysplasia ossificans progressiva, an ...